This year marked an exciting milestone for Celestra Health Systems as we participated for the first time in the American Academy of Neurology (AAN) Annual Meeting in Chicago, the world's largest gathering of neurologists and one of the most influential events in the field of neuroscience and neurological care.
As exhibitors at Booth #3612, we had the opportunity to connect with clinicians, researchers, and industry leaders from around the world, sharing our vision for transforming the way neurological gait is measured and monitored in patients with neurodegenerative diseases.
At Celestra Health Systems, we have a singular focus: developing highly sensitive, real-world measures of neurological gait that provide clinicians and researchers with objective insights into disease progression and treatment effectiveness. Our work is particularly focused on conditions such as Multiple Sclerosis (MS), Parkinson's disease, and other neurological disorders where subtle changes in mobility can provide critical information about a patient's health status.
A highlight of this year's conference was the presentation of our research stemming from two important clinical collaborations.
The first featured results from our U.S.-based Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) study, conducted in partnership with Sanofi and PicnicHealth. The second showcased findings from our Multiple Sclerosis clinical trial with the Technical University of Dresden (TUD) in Germany. Together, these studies reinforce the growing role of digital biomarkers in advancing neurological care and generating objective, clinically meaningful data outside of traditional laboratory settings.
As interest in digital health technologies continues to grow, so does the need for tools that are accurate, patient-friendly, and capable of detecting meaningful changes earlier than conventional approaches. Celestra Health Systems’ platform is designed to meet this need – providing laboratory-grade gait analysis in real-world environments and helping to accelerate both clinical research and patient care.
Our first AAN experience has been an inspiring one. The enthusiasm we encountered from the neurology community reinforces our belief that digital biomarkers will play an increasingly important role in the future of neurological disease management.
We are grateful for the opportunity to share our work, collaborate with leaders in the field, and contribute to a future where earlier detection, more precise monitoring, and better outcomes are possible for patients around the world.
